StockWatch
·
Pharmaceuticals
Quarterly Result6 Aug 2026, 10:41 pm

Lupin Q1 FY27 Sales Surge 33.3% to ₹82,172 Mn

AI Summary

Lupin Limited reported a strong Q1 FY2027 with total sales reaching ₹82,172 Mn, a significant 33.3% year-on-year increase from ₹61,638 Mn in Q1 FY2026. EBITDA grew by 42.8% to ₹25,799 Mn, and Profit After Tax (PAT) rose 16.0% to ₹14,170 Mn. The company saw robust growth across key markets, particularly in the U.S., which accounted for 42% of global sales with a 42.9% YoY increase. Lupin also received 6 ANDA approvals and launched 3 new products in the U.S. market during the quarter. The Managing Director highlighted strong execution, operational excellence, and sustained investments in technology and innovation as drivers for this performance and future growth.

Key Highlights

  • Sales increased by 33.3% YoY to ₹82,172 Mn in Q1 FY2027.
  • EBITDA grew 42.8% YoY to ₹25,799 Mn, with margins improving.
  • U.S. market sales surged 42.9% YoY, contributing significantly to overall revenue.
  • PAT increased 16.0% YoY to ₹14,170 Mn.
  • Company received 6 ANDA approvals and launched 3 products in the U.S.